Pricing Log in Create free account
Friday 6 November 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue
+1.33%
EPS
+418.2%
Free cash flow
−6.83%
Total debt
−42.2%

Quarter to June 2026, against a year earlier

72.75 0.09 +0.12%
Market cap
$11.4B
P/E
62.2×
Fwd P/E
54.2×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revenue by segment Fiscal 2026

  • Protein Sciences
  • Diagnostics and Spatial Biology

Every year since 2009 →

Insider Decisions last twelve months

Sold, $m 0.44
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 1 — — 1 — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 11,410.00
Revenue ttm 1,215.04
Net income ttm 181.86
Free cash flow ttm 263.22
Net debt Q (64.71)
Valuation
P/E 62.15 (above 35: high)
Forward P/E 54.20 (above 35: high)
Price / sales 9.33
Forward P/S Powerpack
Price / FCF 43.09
Price / book 5.38
Financial health
Current ratio Q 4.55 (at or above 1.5: strong)
Debt / equity Q 0.09 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q +1.33% (above 0%: growing)
Operating income growth Q +411.31% (above 0%: growing)
EPS, this year +6.22%
EPS, next year A +15.00% (at or above 15%: strong)
Revenue, next year A +4.36%
EPS, past 5 yrs +5.98%
EPS, next 5 yrs A +7.98%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 9.3×, against a ten-year median of 10.0×; over the ten years it ranged from 6.5× in 2025 to 20.9× in 2021.
P/E against its own 10 years 59.30%
10-year low 10-year high
P/S against its own 10 years 43.75%
10-year low 10-year high
P/B against its own 10 years 42.10%
10-year low 10-year high
EV/Sales against its own 10 years 39.60%
10-year low 10-year high
EV/FCF against its own 10 years 39.64%
10-year low 10-year high

Dividends

Yield
0.44%
Annual rate
0.32
Payout ratio
27.8%
Growth, 2017–25
0.00%/yr
  1. 0.32 ’17
  2. 0.32 ’18 +0
  3. 0.32 ’19 +0
  4. 0.32 ’20 +0
  5. 0.32 ’21 +0
  6. 0.64 ’22 +100
  7. 0.32 ’23 −50
  8. 0.32 ’24 +0
  9. 0.32 ’25 +0
  10. 0.32 ’26e +0
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 204 153 162 265
Receivables 218 241 207 217
Inventory 172 180 189 196
Other 27 43 50 67
621 617 608 744
2023 2024 2025 2026
Payables 26 38 25 27
ST’ Debt — — — —
Other 24 30 34 40
129 159 176 164

Compound Annual Growth %

10y 5y 3y
Sales 9.31% 5.47% 2.25%
Cash Flow 7.32% (3.67%) 4.71%
Earnings 5.70% 5.31% (13.93%)
Book Value 9.14% 6.06% 2.35%

Earnings Trends EPS, adjusted, against the consensus

Q4 FY26 Estimate 0.52 Actual 0.52

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY26 0.42 0.42 Met by 0.00
Q2 FY26 0.43 0.46 Beat by 0.03
Q3 FY26 0.55 0.53 Miss by 0.02
Q4 FY26 0.52 0.52 Met by 0.00
Q1 FY27 0.46 — Reports 4 November 2026

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 0.24 0.24 0.32 0.35 1.16
’25 0.21 0.22 0.14 (0.11) 0.46
’24 0.31 0.17 0.31 0.25 1.05
’23 0.55 0.31 0.43 0.47 1.76
’22 0.42 0.49 0.37 0.38 1.66
’21 0.21 0.29 0.28 0.09 0.87
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 287 296 311 321 1,215
’25 289 297 316 317 1,220
’24 277 273 303 306 1,159
’23 270 272 294 301 1,137
’22 258 269 290 288 1,106
’21 204 224 244 259 931
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 28 82 87 95 292
’25 64 84 41 98 288
’24 59 83 81 75 299
’23 56 64 51 83 254
’22 48 101 73 103 325
’21 66 89 75 122 352
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 22 76 78 87 263
’25 55 78 31 93 257
’24 46 68 65 58 236
’23 47 58 39 73 216
’22 42 91 58 89 280
’21 55 78 64 111 308
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 18.1% a year for ten years. It grew 7.3% a year over the last ten.

Implied
18.1%
10 years, reported
7.3%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

3.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 563 643 714 739 931 1,106 1,137 1,159 1,220 1,215 +8.9% 1,268 1,396 1,541 +8.2%
Gross margin, % 66.53 67.21 66.31 65.41 67.97 68.42 67.72 66.41 64.80 65.77 (0.8) pt
EBT 112 126 112 276 148 301 339 186 98 241 +8.9%
EBT margin, % 19.89 19.59 15.69 37.43 15.92 27.26 29.79 16.02 8.07 19.81 (0.1) pt
Net income 76 126 96 229 140 263 285 168 73 182 +10.2%
Per share, $
Per share, $ Revenue 3.77 4.29 4.72 4.83 6.01 7.05 7.23 7.35 7.74 7.79 +8.4%
Earnings 0.52 0.84 0.64 1.50 0.91 1.73 1.81 1.07 0.47 1.17 +9.5%
Cash flow 0.96 1.14 1.20 1.34 2.27 2.07 1.62 1.90 1.83 1.87 +7.7%
Capex (0.10) (0.14) (0.17) (0.34) (0.29) (0.29) (0.24) (0.40) (0.20) (0.18) +6.9%
Free cash flow 0.86 1.00 1.03 1.00 1.99 1.79 1.38 1.50 1.63 1.69 +7.8%
Book value 6.36 7.20 7.71 9.04 10.14 10.84 12.51 13.12 12.18 13.52 +8.7%
Shares, m 149 150 151 153 155 157 157 158 158 156 +0.5%
Valuation, ×
Valuation, × P/E 60.27 44.38 82.72 44.01 124.04 49.95 44.85 67.56 111.85 60.38 69.0
P/S 7.79 8.64 11.07 13.66 18.74 12.30 11.29 9.74 6.65 9.07 10.9
P/B 4.62 5.15 6.78 7.30 11.10 7.99 6.52 5.46 4.22 5.23 6.4
EV/Sales 8.12 8.88 11.55 13.77 18.86 12.30 11.43 9.90 6.81 9.03 11.1
EV/FCF 35.56 38.23 52.79 66.29 57.03 48.52 60.09 48.59 32.36 41.66 48.1
Cash, $m
Cash, $m Operating cash flow 144 170 182 205 352 325 254 299 288 292 +8.2%
Capex (15) (21) (25) (52) (44) (45) (38) (63) (31) (29) +7.4%
Free cash flow 129 149 156 153 308 280 216 236 257 263 +8.3%
Balance, $m
Balance, $m Working capital 213 319 311 414 358 430 493 458 432 581 +11.8%
Net debt 186 157 339 86 110 9 146 166 184 (65) n/m
Shareholders’ equity 950 1,079 1,166 1,381 1,571 1,701 1,967 2,069 1,919 2,108 +9.3%
Returns, %
Returns, % ROA 5.66 8.01 5.53 11.72 6.55 11.94 11.56 6.29 2.79 7.07 +1.4 pt
ROIC 6.64 6.88 6.09 6.71 8.82 10.84 8.85 5.78 3.04 7.70 +1.1 pt
ROE 8.32 12.44 8.56 18.01 9.51 16.63 15.56 8.33 3.68 9.03 +0.7 pt
People
People Employees 1,800 2,000 2,250 2,300 2,600 3,000 3,050 3,100 3,100 3,000 +5.8%
Revenue/emp, $m 0.31 0.32 0.32 0.32 0.36 0.37 0.37 0.37 0.39 0.41 +2.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Business profile

Updated

Bio-Techne develops, manufactures and sells life-science reagents, instruments and services used in research, diagnostics and bioprocessing markets worldwide. Its tools help researchers study biological processes, support drug discovery, and enable clinical tests and diagnoses.

The company operates through Protein Sciences and Diagnostics and Spatial Biology. Protein Sciences supplies biological reagents, protein-analysis tools and immunoassays used in research, diagnostics, cell therapy and gene therapy. Its products include proteins, cytokines, growth factors, antibodies, small molecules, cell-selection technologies, automated western blot systems and multiplex immunoassays.

Where the money comes from and where it goes Fiscal 2026

Fiscal 2026: revenue by segment, and margins
Protein Sciences 875 71.98%
Diagnostics and Spatial Biology 336 27.68%
Gross margin 65.77%
Operating margin 20.73%
Pre-tax margin 19.81%

Revenue by segment since 2009

Bio-Techne Corp vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TECH Bio-Techne Corp $11.4B 62.2× 54.2× +1.33% (above 0%: growing) n/m −6.83% (below 0%: shrinking) 65.82% 23.13%
SMMT Summit Therapeutics PLC $11.3B — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −112.80% (below 0%: shrinking) 0.00% 0.00% Compare
KYMR Kymera Therapeutics, Inc. $10.9B — (loss-making) — (loss-making) +466.40% (above 0%: growing) n/m −186.64% (below 0%: shrinking) 100.00% 0.00% Compare
BMRN BioMarin Pharmaceutical Inc. $10.9B — (loss-making) 32.7× +32.02% (above 0%: growing) n/m −52.25% (below 0%: shrinking) 79.95% (8.01%) Compare
PCVX Vaxcyte, Inc. $9.8B — (loss-making) — — n/m −92.55% (below 0%: shrinking) 0.00% 0.00% Compare
TGTX TG Therapeutics, Inc. $8.9B 19.1× 62.4× +70.27% (above 0%: growing) −73.68% (below 0%: shrinking) +427.05% (above 0%: growing) 82.86% 9.02% Compare
IBRX ImmunityBio, Inc. $8.5B — (loss-making) — (loss-making) +93.91% (above 0%: growing) n/m +13.38% (above 0%: growing) 99.42% (120.41%) Compare
TWST Twist Bioscience Corporation $7.9B — (loss-making) — (loss-making) +23.24% (above 0%: growing) n/m −7.23% (below 0%: shrinking) 52.76% (30.65%) Compare
CAI Caris Life Sciences,�Inc. $7.4B 77.7× 254× +26.99% (above 0%: growing) −40.33% (below 0%: shrinking) −140.21% (below 0%: shrinking) 0.00% 7.01% Compare
Median of peers $9.3B — 62.4× +32.02% — −72.40% 66.36% 0.00%

All 621 Biotechnology stocks →

From the latest earnings call

Updated

  • Kim Kalderman said large pharmaceutical demand remained strong and U.S. academic trends stabilized, while emerging-biotech spending had not yet reflected improved funding.
  • Jim Hippel said Bio-Techne expected approximately flat Q4 organic growth, with the timing of biotech customer spending remaining the largest factor for growth.

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 112.18%
Held by the ten largest 54.57%
Holder Shares Stake Change
Vanguard 18.15m 11.63% +55.75k
BlackRock 14.03m 8.99% +1.76m
Fidelity (FMR) 12.79m 8.20% +4.89m
Goldman Sachs 7.34m 4.70% +5.40m
HBK INVESTMENTS L P 6.83m 4.37% +6.83m
Morgan Stanley 6.37m 4.08% −2.16m
State Street 5.98m 3.83% +111.97k
Geode Capital Management 5.35m 3.43% +239.04k
Invesco 4.99m 3.19% +397.72k
Ruane, Cunniff & Goldfarb L.P. 3.35m 2.15% −43.16k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed 19 September 2025

Ownership

Directors and executive officers, together 1.30%
Malvern, PA 11.70%
New York, NY 7.70%
Baltimore, MD 6.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Bio-Techne Corp (TECH) Latest News

2 Nov

Impact 4 · · Zacks

26 Oct

Impact 4 · · Barchart
Impact 3 · · StockStory

9 Oct

Impact 4 · · pharmaceutical-technology.com
Impact 3 · · StockStory

8 Oct

Impact 4 · · PR Newswire

30 Sep

Impact 3 · · Zacks

28 Sep

Impact 3 · · StockStory

25 Sep

Impact 4 · · Insider Monkey

24 Sep

Impact 5 · · Barchart

23 Sep

Impact 4 · · PR Newswire
Impact 3 · · StockStory

22 Sep

Impact 4 · · CNW Group
Impact 4 · · PR Newswire

13 Aug

Impact 3 ·

12 Aug

Impact 3 ·

8 Jul

Impact 3 ·

26 Jun

Impact 5 · · qz.com
Impact 5 ·
Impact 4 · · Barchart
Impact 4 · · The Daily Upside

25 Jun

Impact 5 · · Insider Monkey
Impact 5 · · The Motley Fool
Impact 5 · · Barrons.com
Impact 5 · · Barrons.com
Impact 5 · · medicaldevice-network.com
Impact 5 · · MT Newswires
Impact 5 · · Barrons.com
Impact 5 · · InvestorsHub
Impact 5 · · PR Newswire

TECH metrics, ten years each

stockrow.com/TECH · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com